Disease & Cancer Genetics
Research and Development
Virtual trial Design / Real-World Evidence
Post Market Surveillance
Digital & Virtual Life Sciences
Our mission is to ensure that products developed within the life science industry are able to reach through every patient demographic to bolster health equity and effective patient outcomes.
At Rubix LS, we’re solving the problems of ensuring that we can shorten the gap between product innovations and the inclusivity of patients that are in need of therapeutic interventions through data.
Our focus is simple: Patient Innovation First. Always.
Data. Absolute. Auditable. Accurate
We’re putting the power of science, data, intelligence, and discovery at work for you in one transparent process. Sponsors, CROs, clinicians, patients and payers are looking for more than just healthcare options – it’s all about healthcare outcomes. See how the data we provide, merged with Artificial Intelligence and Machine Learning, are powering outcomes to be more inclusive and designing inclusive structures to bring wider demographics into therapeutic data sets.
Disease & Cancer Genetics
Drive knowledge of how patient demographics, environmental factors, and patient biological maps intersect on understanding disease behaviors and patient profiles.
Research and development
Use our AI/ML-driven process to accelerate your lead asset development efforts and reduce the time of discovery by 31%*
Real world evidence / virtual clinical trials
Our data harmonizes both historical and situational data sets that will equip your clinical teams to create targeted approaches for clinical trial success. We then drive efforts to create virtual and hybrid clinical trials in coordination with CRO’s and provider networks.
Post Market surveillance
Often overlooked, Phase IV trial adherence are essential to the long-term viability of the product. 20-30% of clinical trials are accurately represented with conducting and concluding Phase IV trials to inform public and private stakeholders for product efficacy. Use our data to drive a feedback loop to continue effective product development efforts.
Supporting the federal markets
As the world shifts to defend against new emerging health threats, government agencies are grappling with new ways to overcome those challenges. Agile convergence of digital and scientific innovation becomes a crucial vehicle to deliver outcomes-based approaches to achieve mission objectives.
We’re not just innovators, we’re also creating the entrepreneurial structure into agencies that will increase strength and expansion into programs that will catapult science and technology forward.
Latest News & Articles
Rubix LS enters into an agreement to support infectious disease data research
July 17, 2019 - Lawrence, MA - Today, Rubix LS is announcing that they're expanding their virtual clinical trial and disease intelligence platform that will include the nations: Morocco, Kenya, Indonesia and Brazil as part of a wider United Nations, http://www.un.org, health...
An Interview: Digital Life Sciences & Inclusive Patient Outcomes from the CEO
Recently, the CEO had an opportunity to share his insights with Devin Thorpe, founder of Your Mark on The World, a non-profit group in which the sole mission is: "is to solve the world's biggest problems before 2045 by identifying and championing the work of...
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.